SCHEMBL6538645

SCHEMBL6538645

CC(C)(C)COc1ccc(C(=O)O)c(Cc2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 1/20 0.47
LTB4R2 Q9NPC1 1/20 0.47
MAOB P27338 1/20 0.44
PTPN1 P18031 3/20 0.43
PTPN2 P17706 1/20 0.43
PTPN6 P29350 1/20 0.43
TSHR P16473 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
NR4A2 P43354 1/20 0.40
PTPN11 Q06124 1/20 0.40
PDK2 Q15119 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
HNF4A P41235 1/20 0.39
MCL1 Q07820 2/20 0.39
BCL2A1 Q16548 1/20 0.39
SLC16A3 O15427 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10493530 0.84 LTB4R (0.49) LTB4RLTB4R2MAOBPTPN1PTPN2
SCHEMBL542829 0.83 LTB4R (0.60) LTB4RLTB4R2MAOBALDH1A1NR4A2
SCHEMBL3098374 0.81 MTNR1A (0.58) PTPN1PTPN2PTPN6TSHRALDH1A1
SCHEMBL6539246 0.79 MAPK1 (0.52) LTB4RLTB4R2MAOBPTPN1PTPN2
SCHEMBL20556382 0.77 RXRB (0.45) TSHRALDH1A1MCL1KDM4E
SCHEMBL22976873 0.76 TSHR (0.45) LTB4RLTB4R2MAOBPTPN1PTPN2
SCHEMBL2834568 0.76 KDM4E (0.54) LTB4RLTB4R2PTPN1PTPN2PTPN6
SCHEMBL8889874 0.75 KMT2A (0.53) PTPN1PTPN2PTPN6TSHRALDH1A1
SCHEMBL21526681 0.75 ELANE (0.49) LTB4RLTB4R2MAOBPTPN1PTPN2
SCHEMBL7322745 0.74 PARP10 (0.53) MAOBPDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB LTB4R 496/4885LTB4R2 378/4885MAOB 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.